ARN 6039

Drug Profile

ARN 6039

Alternative Names: ARN-6039; BOS 172767

Latest Information Update: 20 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Arrien Pharmaceuticals
  • Developer Arrien Pharmaceuticals; Boston Pharmaceuticals
  • Class Antipsoriatics; Small molecules
  • Mechanism of Action Nuclear receptor subfamily 1 group F member 3 inverse agonists; Th17 cell modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Autoimmune disorders; Multiple sclerosis
  • Preclinical Psoriasis

Most Recent Events

  • 13 Mar 2018 Phase-I clinical trials in Autoimmune disorders (In volunteers) in United Kingdom (PO, Capsule) (NCT03464058)
  • 13 Mar 2018 Phase-I clinical trials in Autoimmune disorders (In volunteers) in United Kingdom (PO, Tablet) (NCT03464058)
  • 28 Jun 2017 ARN 6039 licensed to Undisclosed company worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top